SGLT-2 Inhibitors Reduce Glaucoma Risk in Type 2 Diabetes Patients
New AAO 2023 data suggests drugs like dapagliflozin and empagliflozin may provide greater protection against glaucoma than GLP-1 agonists or DDP-4 inhibitors.
United States San Francisco Kathleen Eng Harvard Medical School American Academy Of Ophthalmology Association For Research
Source: hcplive.com